Development of a Bamlanivimab Infusion Process in the Emergency Department for Outpatient COVID-19 Patients
Open Access
- 27 December 2021
- journal article
- research article
- Published by MDPI AG in Healthcare
- Vol. 10 (1) , 42
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has prompted the creation of new therapies to help fight against the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Bamlanivimab is a SARS-CoV-2 monoclonal antibody that is administered as an intravenous infusion to ambulatory patients with mild or moderate COVID-19, but a concern that arose was deciding the optimal location for patients to receive the medication. This report describes the development and implementation of a bamlanivimab infusion center in the emergency department of three hospitals in Orange County, California, shortly after bamlanivimab received emergency use authorization. As a result, a total of 601 patients received bamlanivimab in one of these three emergency departments between December 2020 to April 2021. The emergency department was shown to be an optimal setting for administration of bamlanivimab due to its convenience, accessibility, and capabilities for monitoring patients.Keywords
This publication has 11 references indexed in Scilit:
- Emergency department administration of COVID-19 antibody therapies: Early experienceThe American Journal of Emergency Medicine, 2021
- Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living FacilitiesJAMA, 2021
- Neutralizing monoclonal antibodies for treatment of COVID-19Nature Reviews Immunology, 2021
- A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19New England Journal of Medicine, 2021
- COVID-19 Monoclonal Antibody Infusions: A Multidisciplinary Initiative to Operationalize EUA Novel Treatment Options2021
- Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19JAMA, 2021
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19New England Journal of Medicine, 2021
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19New England Journal of Medicine, 2021
- Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task ForceJournal of Crohn's and Colitis, 2020
- Human neutralizing antibodies elicited by SARS-CoV-2 infectionNature, 2020